A Phase 3 interventional study of Terconazole and Metronidazole in Vaginal Infection, sponsored by Curatek Pharmaceuticals, LLC. Completed at 51 sites in United States. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-08-04.
Sponsored by Curatek Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Vaginitis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Vaginitis · United States.
Among the 38 studies in Vaginitis with a site in United States, this one is the 6th largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2015, is one of 8 in phase 3, and was the 17th registered.
98 studies on the registry are indexed under Vaginitis; 12 are open to participants now.
Browse Vaginitis studies →4 of the 38 studies in Vaginitis with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
University of Virginia · Sites in United States
Ages 18+ · Women only
Albert Einstein College of Medicine · Sites in United States
Ages 40–70 · Women only · Healthy volunteers
Atlantic Health System · Sites in United States
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Vaginitis studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 12 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 8 · Phase 4 4
First in 1999; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 475 is above the median of 108 across 71 interventional studies indexed under Vaginitis.
Median enrollment 77 across the 33 interventional studies, 299 across the 5 observational. Of the 27 that completed or were terminated, 12 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 38 have an industry lead sponsor. The 10 most frequent:
Curatek Pharmaceuticals, LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
Curatek Pharmaceuticals, LLC has 3 studies filed under Vaginitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Vaginitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies in Vaginitis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One applicator full at bedtime
Drug: Terconazole
One applicator full at bedtime
Drug: Metronidazole
One applicator full at bedtime
Drug: Terconazole/metronidazole
Drug page: Metronidazole
Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit
The percentage of participants with clinical cure of both bacterial vaginosis (BV) AND vulvovaginal candidiasis (VVC) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV is defined as: discharge has returned to normal/physiologic, negative whiff test, and saline wet mount is \<20% clue cells. Clinical cure of VVC is defined as resolution of all signs and symptoms attributable to vulvovaginal candidiasis
Time frame: 7-14 days after beginning treatment
Cure of the BV Component of Mixed Infection
The percentage of participants with both BV and VVC who had clinical cure of bacterial vaginosis (BV) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV was defined as: 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells
Time frame: 7-14 days after beginning treatment
Cure of the VVC Component of Mixed Infection
The percentage of participants with both BV and VVC who had clinical cure of VVC was compared between the combination therapy and the two single entity treatments.Clinical cure of VVC was defined as complete resolution of all signs and symptoms attributable to VVC
Time frame: 7-14 days after beginning treatment
Microbiologic and Mycologic Cure
The percentage of participants with both microbiologic and mycologic cure was compared between the combination therapy and the two single entity treatments. Yeast cultures were performed and Gram stains of vaginal fluid were graded according to Nugent's criteria. Microbiologic cure requires normal Nugent gram stain score and mycologic cure requires negative yeast culture.
Time frame: 7-14 days after beginning treatment
Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit
Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.
Time frame: 7-14 days after beginning treatment
Number of Participants With Treatment Emergent Adverse Events
Adverse events were collected at study visits, from subject diaries and from spontaneous reports
Time frame: Any time during study participation (up to 30 days)
| Milestone | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Started | 159 | 159 | 157 |
| Completed | 83 | 84 | 82 |
| Not completed | 76 | 75 | 75 |
| Withdrew: Normal gram stain or neg yeast culture | 66 | 64 | 67 |
| Withdrew: Positive for std at baseline | 7 | 11 | 7 |
| Withdrew: Lost to follow-up | 3 | 0 | 1 |
The percentage of participants with clinical cure of both bacterial vaginosis (BV) AND vulvovaginal candidiasis (VVC) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV is defined as: discharge has returned to normal/physiologic, negative whiff test, and saline wet mount is \<20% clue cells. Clinical cure of VVC is defined as resolution of all signs and symptoms attributable to vulvovaginal candidiasis
| Participants | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit | 31 | 29 | 43 |
The percentage of participants with both BV and VVC who had clinical cure of bacterial vaginosis (BV) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV was defined as: 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells
| Participants | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Cure of the BV Component of Mixed Infection | 38 | 46 | 54 |
The percentage of participants with both BV and VVC who had clinical cure of VVC was compared between the combination therapy and the two single entity treatments.Clinical cure of VVC was defined as complete resolution of all signs and symptoms attributable to VVC
| Participants | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Cure of the VVC Component of Mixed Infection | 52 | 37 | 53 |
The percentage of participants with both microbiologic and mycologic cure was compared between the combination therapy and the two single entity treatments. Yeast cultures were performed and Gram stains of vaginal fluid were graded according to Nugent's criteria. Microbiologic cure requires normal Nugent gram stain score and mycologic cure requires negative yeast culture.
| Participants | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Microbiologic and Mycologic Cure | 19 | 5 | 24 |
Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.
| Participants | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit | 49 | 44 | 49 |
Adverse events were collected at study visits, from subject diaries and from spontaneous reports
| Participants | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 44 | 40 | 44 |
Collected over The safety population includes all participants randomized to treatment and administered at least one dose of study drug, and includes subjects who had a negative yeast culture and/or normal gram stain at the baseline visit. Adverse events were collected over the entire course of the study (up to 30 days after beginning treatment).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Terconazole Vaginal Gel | 0/149 (0%) | 1/149 (0.7%) | 5/149 (3.4%) |
| Metronidazole Vaginal Gel | 0/151 (0%) | 0/151 (0%) | 6/151 (4%) |
| Terconazole/Metronidazole Vaginal Gel | 0/154 (0%) | 0/154 (0%) | 8/154 (5.2%) |
| Event | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/149 | — | — |
| Event | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel |
|---|---|---|---|
| Vulvovaginal burning sensationReproductive system and breast disorders | 5/149 | 6/151 | 8/154 |
modified intent-to-treat (mITT) population includes all subjects randomized to treatment and administered at least one dose of study drug. In addition, subjects must have a Nugent score of 4 or more on Baseline visit Gram stain slide and a Baseline visit yeast culture positive for Candida species.
| Age, Continuous(years) | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel | Total |
|---|---|---|---|---|
| Mean | 31.5 ± 9.17 | 31.0 ± 9.43 | 32.6 ± 10.57 | 31.7 ± 9.72 |
| Sex: Female, Male(Participants) | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel | Total |
|---|---|---|---|---|
| Female | 83 | 84 | 82 | 249 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel | Total |
|---|---|---|---|---|
| Hispanic or Latino | 15 | 15 | 9 | 39 |
| Not Hispanic or Latino | 68 | 69 | 73 | 210 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 0 | 3 |
| Asian | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 52 | 54 | 50 | 156 |
| White | 30 | 26 | 28 | 84 |
| More than one race | 0 | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Terconazole Vaginal Gel | Metronidazole Vaginal Gel | Terconazole/Metronidazole Vaginal Gel | Total |
|---|---|---|---|---|
| United States | 83 | 84 | 82 | 249 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Jun 2015, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2020, 2 years 2 months after primary completion. A results delay was requested in Jun 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole
Curatek Pharmaceuticals, LLC